
Doximity (DOCS) Stock Forecast & Price Target
Doximity (DOCS) Analyst Ratings
Bulls say
Doximity Inc. has demonstrated robust growth, particularly in its point-of-care (POC) and formulary offerings, which experienced more than 100% increase during the buying season as of February 2024. The company's stock has shown a positive trend, increasing by 3.2% since September 8, indicating a favorable market reaction to recent developments. Furthermore, the guidance for the second quarter appears not only achievable but also potentially offers upside, bolstered by expanding service offerings that enhance visibility and encourage upfront purchasing.
Bears say
Doximity Inc. faces a negative outlook due to the uncertain economic environment, causing pharmaceutical clients to issue downward guidance revisions for fiscal years 2023 and 2024. Additionally, the company is trading at a premium compared to its software peers, raising concerns about potential volatility if it fails to meet high investor expectations. The market will closely monitor Doximity's performance, and any failure to deliver favorable results or raise guidance could lead to significant disappointment among investors.
This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.
Doximity (DOCS) Analyst Forecast & Price Prediction
Start investing in Doximity (DOCS)
Order type
Buy in
Order amount
Est. shares
0 shares